Property owner wins battle over Santa Barbara short-term rental
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
GeoLinks using Silicon Valley-style office to attract employees
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Travel show features Oxnard as family destination
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
CalAmp reports revenue decline but net income up
Information technology company CalAmp reported on Sept. 28 a slight drop in revenue for its second quarter but a dramatic increase in net income, bringing in $12.2 million, or 34 cents per share. The company, which has operations in Oxnard, brought in $89.8 million during the quarter, down slightly from $90.5 million in the second Read More →
Museum of Ventura County replaces board with 11 new members
Updated at 10:20 a.m. Sept. 29: The Museum of Ventura County has replaced its board of directors and elected 11 new board members, it announced in a news release Sept. 28. The museum has faced financial woes and possible closure in the past few years. It streamlined its budget to $1.1 million as of May Read More →
Amgen settles with AbbVie over Humira biosimilar
Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →
Amgen agrees to develop biosimilars for Chinese market
Increasing its global footprint in the biosimilars market, Amgen announced Sept. 26 that it had formed an exclusive co-development agreement with Chinese drug manufacturer Simcere Pharmaceutical Group. The agreement aims to bring four oncology and inflammation biosimilars in Amgen’s portfolio to commercialization in China. The Thousand Oaks-based biotechnology company will produce and submit approval applications Read More →
